All In Biotech

Drug Trial Radar · NCT04103086

ARomatherapy for Cognitive Trajectory in Chinese After Percutaneous Coronary Intervention (ARCTIC-PCI)

ARomatherapy for Cognitive Trajectory in Chinese After Percutaneous Coronary Intervention (ARCTIC-PCI): a Randomized, Double-blind, Placebo-controlled Trial

Last checked: Nov 20, 2026Latest source record: Sep 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 660 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

660

Planned (sponsor's estimate)

Start

Dec 2019

Primary completion

Dec 2020

Study completion Jun 2021

Sponsor

Lead sponsor
Beijing Anzhen HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Peking University
First posted
Sep 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ARCTIC-PCI (Aromatherapy for Cognitive Trajectory in Chinese after Percutaneous Coronary Intervention) trial is a randomized, double-blind, 2-arm, parallel group, placebo-controlled study to evaluated the effects of aromatherapy in improving cognitive function in post-percutaneous coronary intervention (PCI) patients. The study will recruit 660 patients who undergo a PCI at the Department of Cardiology in Beijing Anzhen Hospital. Baseline information will be collected prior to PCI, all eligible participants undergoing PCI will be randomly assigned in a 1:1 ratio before hospital discharge to receive aromatherapy (70% menthol and 30% propanediol) or placebo (10% menthol and 90% propanediol). The treatment will last for 6 months in both groups. Cognitive function measurement will be conducted by blinded assessors at baseline (1-3 days before PCI) and at 3- and 6- month after PCI. The primary outcome will be the change in overall cognitive function (MOCA score) from baseline to 6-month after PCI.

Conditions

  • Percutaneous Coronary Intervention

Interventions

  • AromatherapyDrug

    Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge. The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal.

  • PlaceboDrug

    Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in the overall cognitive function at 6 months after PCITime frame: before and after 6-month intervention
  2. Changes in the overall cognitive function at 3 months after PCITime frame: before and after 6-month intervention
  3. Changes in the memory function at 3- and 6- month after PCITime frame: before and after 3- and 6-month intervention
  4. Changes in the executive function: semantic fluency, at 3- and 6- month after PCITime frame: before and after 3- and 6-month intervention
  5. Changes in the executive function: visual attention, at 3- and 6- month after PCITime frame: before and after 3- and 6-month intervention
  6. Changes in the orientation function at 3- and 6- month after PCITime frame: before and after 3- and 6-month intervention
  7. The proportion of patients with mild cognitive impairment at 3- and 6- month after PCITime frame: before and after 3- and 6- month intervention

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.